Skip to main content

Table 1 Baseline characteristics of 73 patients with LS-SCLC treated with early CCRT

From: Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

Variable Result
Age, median (range), years
 ≥ 70/ < 70 years
66 (34–77)
19/54
Sex, male/female 55/18
ECOG-PS, 0/1/2 42/28/3
Clinical stage, I/II/IIIa 0/15/58
Brinkmann index, ≥ 400/ < 400 71/2
Preexistence of ILAs, yes/no 11/62
V20, median (range), % 24 (13–36)
(n = 72)
Number of patients receiving AHF 72
Number of patients receiving PCI 45
Chemotherapy regimen, CDDP/CBDCA 72/1
  1. aClinical staging according to the 7th edition of the TNM classification of lung cancer [9]. LS-SCLC, limited-stage small-cell lung cancer
  2. CCRT, concurrent chemoradiotherapy; ECOG-PS, Eastern Cooperative Oncology Group performance status; ILA, interstitial lung abnormality; V20, percentage of normal lung receiving at least 20 Gy; AHF, accelerated hyperfractionation; PCI, prophylactic cranial irradiation; CDDP, cisplatin; CBDCA, carboplatin